drugset / Trial / NCT04454866

Penehyclidine for Prevention of Nausea and Vomiting After Bimaxillary Surgery

NCT04454866 ↗

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Postoperative nausea and vomiting (PONV) is a common complication after surgery. Patients undergoing orthognathic surgery are reported to have a high rate of PONV, especially those undergoing bimaxillary surgery. Activation of cholinergic system plays an important role in the development of PONV. Penehyclidine is an muscarinic antagonists which selectively block M1 and M3 receptors and is commonly used to decrease oral secretion. The investigators hypothesize that continuously administrated penehyclidine during perioperative period can reduce the incidence of PONV in patients undergoing bimaxillary surgery.

Timeline

Start
2020-07-07
Primary completion
2021-03-15
Completion
2021-04-15

Outcome

Met primary endpoint

paper The incidence was significantly lower in the Bolus group than in the Control group (RR 0.66; 95% CI 0.51-0.86; adjusted P = 0.003) PMID 34738161 ↗

paper the Infusion group than in the Control group (RR 0.46; 95% CI 0.33-0.63; adjusted P < 0.001) PMID 34738161 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Penehyclidine Small molecule 0.25 mg Intravenous
Subject Penehyclidine Small molecule 0.5 mg Intravenous

Indications

No indication recorded.